<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034177</url>
  </required_header>
  <id_info>
    <org_study_id>SON-8184-1065</org_study_id>
    <nct_id>NCT00034177</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium</brief_title>
  <official_title>Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <brief_summary>
    <textblock>
      Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly&#xD;
      S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced,&#xD;
      metastatic, or recurrent transitional cell carcinoma of the urothelium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to determine the objective response rate, to determine time to&#xD;
      disease progression, duration of response, and survival, and to identify the maximum&#xD;
      tolerated weekly dose and principal toxicities of S-8184 in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate; time to disease progression; duration of response; survival; toxicities</measure>
    <time_frame>After all patients completed treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine time to disease progression</measure>
    <time_frame>After all patients have completed treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Urologic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-8184 Paclitaxel Injectable Emulsion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Arm: TOCOSOL Paclitaxel</intervention_name>
    <description>Doses of 80, 100 and 120mg/m2</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of transitional cell carcinoma of the urothelium including renal&#xD;
             pelvis, ureter, bladder, or urethra&#xD;
&#xD;
          -  Locally advanced with lymph node disease(unresectable T3-4, N+, M0); metastatic (T&#xD;
             any, N any, MI); or locally recurrent disease following initial definitive therapy&#xD;
&#xD;
          -  One and only one prior systemic cytotoxic chemotherapy regimen (note that intravesical&#xD;
             treatments are not included in the definition of systemic cytotoxic chemotherapy)&#xD;
&#xD;
          -  Failure of first line systemic chemotherapy with a platinum-containing combination&#xD;
             regimen consisting of MVAC or cisplatin/gemcitabine with cisplatin dosed at 60 mg/m2&#xD;
             or higher per cycle&#xD;
&#xD;
          -  Adult (18 years of age or older) patients&#xD;
&#xD;
          -  Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater&#xD;
             than 100,000/mm3)&#xD;
&#xD;
          -  Serum creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit&#xD;
             of institutional normal values&#xD;
&#xD;
          -  ECOG performance status of 0 - 2&#xD;
&#xD;
          -  Bidimensional measurable disease&#xD;
&#xD;
          -  Patients who have signed an IRB / Ethics Committee approved informed consent&#xD;
&#xD;
          -  Life expectancy at least 12 weeks&#xD;
&#xD;
          -  Patient has fully recovered from any previous surgery (at least 4 weeks since major&#xD;
             surgery)&#xD;
&#xD;
          -  Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients&#xD;
             of child bearing potential must use a medically effective form of contraception during&#xD;
             the treatment.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received any taxane-containing preparation including Taxol&#xD;
             (paclitaxel) or Taxotere (docetaxel)&#xD;
&#xD;
          -  Patients with intracranial metastases&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
&#xD;
          -  Patients with peripheral neuropathy NCI-CTC grade 2 or greater&#xD;
&#xD;
          -  Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal&#xD;
             therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of&#xD;
             study entry&#xD;
&#xD;
          -  Patients who have had an investigational agent within 4 weeks of study entry&#xD;
&#xD;
          -  Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>April 23, 2002</study_first_submitted>
  <study_first_submitted_qc>April 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2002</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Monica Krieger, VP Regulatory Affairs</name_title>
    <organization>OncoGenex Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

